Home › Compare › CGCLF vs ABBV
CGCLF yields 4.64% · ABBV yields 3.06%● Live data
📍 CGCLF pulled ahead of the other in Year 1
Combined, CGCLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGCLF + ABBV for your $10,000?
Central Glass Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of flat glass and chemical products for customers in Japan, North America, Europe, Asia, and internationally. The company operates in two segments, Glass Business and Chemicals Business. It offers architectural glass products, including soundproof, laminated, security, tempered, fire protection, high transparent, and special construction, as well as eco-glass and anti-fog mirrors; automotive glass products comprising laminated, tempered, UV cut, privacy, IR cut, water repellent, acoustic, laminated side, panoramic roof, de-icer, and defogging glasses, as well as glass antenna and module windows; and glass fiber and glass wool products. The company also provides chemical products; fine chemicals, such as aromatic products, aliphatic compounds, chiral compounds, trifluoromethanesulfonic acid and derivatives, aromatic monomers, aliphatic monomers, fluorine resins, and reagents; fertilizers; and microbial control agents and materials. The company was formerly known as Ube Soda Industry Co., Ltd. and changed its name to Central Glass Co., Ltd. in 1963. Central Glass Co., Ltd. was incorporated in 1936 and is headquartered in Tokyo, Japan.
Full CGCLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.